AU5946999A - Tumour therapy and imaging - Google Patents

Tumour therapy and imaging

Info

Publication number
AU5946999A
AU5946999A AU59469/99A AU5946999A AU5946999A AU 5946999 A AU5946999 A AU 5946999A AU 59469/99 A AU59469/99 A AU 59469/99A AU 5946999 A AU5946999 A AU 5946999A AU 5946999 A AU5946999 A AU 5946999A
Authority
AU
Australia
Prior art keywords
imaging
tumour therapy
tumour
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59469/99A
Inventor
Kenneth Dawson Bagshawe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzacta R&D Ltd
Original Assignee
Enzacta R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzacta R&D Ltd filed Critical Enzacta R&D Ltd
Publication of AU5946999A publication Critical patent/AU5946999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU59469/99A 1998-06-11 1999-06-11 Tumour therapy and imaging Abandoned AU5946999A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9812550 1998-06-11
GBGB9812550.3A GB9812550D0 (en) 1998-06-11 1998-06-11 Tumour therapy and imaging
PCT/GB1999/001870 WO1999064065A2 (en) 1998-06-11 1999-06-11 Tumour therapy and imaging

Publications (1)

Publication Number Publication Date
AU5946999A true AU5946999A (en) 1999-12-30

Family

ID=10833545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59469/99A Abandoned AU5946999A (en) 1998-06-11 1999-06-11 Tumour therapy and imaging

Country Status (3)

Country Link
AU (1) AU5946999A (en)
GB (1) GB9812550D0 (en)
WO (1) WO1999064065A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308363D0 (en) * 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
WO2018071435A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63219374A (en) * 1987-03-09 1988-09-13 Takara Shuzo Co Ltd Chemically modified carboxypeptidase and use thereof
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
JP2662311B2 (en) * 1989-08-07 1997-10-08 デビオファルム ソシエテ アノニム Novel biologically active drug / polymer derivative and method for producing the same
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy

Also Published As

Publication number Publication date
WO1999064065A2 (en) 1999-12-16
WO1999064065A3 (en) 2000-06-29
GB9812550D0 (en) 1998-08-05

Similar Documents

Publication Publication Date Title
AU2655599A (en) Endoluminal implant with therapeutic and diagnostic capability
AU1196400A (en) Improved radioactive therapeutic seeds and methods of making the same
AU8026600A (en) Brachytherapy instrument and methods
AU2001228205A1 (en) Linac neutron therapy and imaging
AU6528800A (en) Methods and apparatuses for radiation treatment
AU2320299A (en) Device and method for radiation therapy
AU715620C (en) Therapeutic methods and uses
AU2001287890A1 (en) Radiotherapy apparatus and collimator set therefor
AU6460299A (en) Radiation device for therapeutic and cosmetic purposes
AU1671600A (en) Electromagnetic radiation therapy
AU7058000A (en) 13 human colon and colon cancer associated proteins
AU1710600A (en) Enhanced radiation therapy
AU5333298A (en) Compositions and methods for tumour therapy
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU5946999A (en) Tumour therapy and imaging
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
AU4629399A (en) Substituted piperazones and their therapeutic uses
GB9703633D0 (en) Cancer therapy
AU2227999A (en) Human ependymin
AU2453399A (en) Bone cancer therapy
AU1464399A (en) Reagent for tumor therapy and/or imaging
AU4860299A (en) (zap-3) tumor associated genes and their uses
EP1112250A4 (en) Therapeutic compounds and methods
AU2918199A (en) Tumour imaging and therapeutic agents
AU1579700A (en) Cytokine combination therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase